← Search & browse all drugs

technetium (99mTc) bicisate

V09AA02

Forms & Strengths

Kit for the preparation of technetium Tc 99m bicisate injection
Lyophilized powder in a vial containing 0.9 mg bicisate dihydrochloride

Adult Dosing

740 to 1110 MBq (20 to 30 mCi) administered as a single intravenous injection
Imaging typically performed 15 to 90 minutes post-injection

Pediatric Dosing

Safety and efficacy in pediatric patients have not been established
Use in children is generally avoided unless clearly indicated and calculated based on body weight

Indications

Localization of regional cerebral blood flow in evaluation of stroke
Assisting in the localization of seizure foci in patients with epilepsy

Mechanism of Action

Lipophilic complex that crosses the blood-brain barrier intact
Converted into more polar, hydrophilic metabolites by enzymatic hydrolysis within brain cells
Trapped intracellularly in proportion to regional cerebral blood flow

Contraindications

Hypersensitivity to technetium Tc 99m bicisate or any component of the formulation
Pregnancy, unless the potential benefit outweighs the unknown risks of radiation exposure

Adverse Reactions

Generally well-tolerated with rare adverse events
Headache, dizziness, and nausea reported infrequently
Transient injection site pain or erythema

Drug Interactions

Drugs that alter regional cerebral blood flow (e.g., vasodilators, vasoconstrictors, CNS active agents) may alter radiotracer distribution
No specific pharmacokinetic drug-drug interactions documented

Curated Content: Needs Vetting Before Put to Clinical Use